WorldPharmaNews
  • Home
  • Business
  • Research
  • Events
  • Regulatory

Bristol-Myers Squibb

Bristol-Myers SquibbBristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.

www.bms.com.

Bristol-Myers Squibb RSS Channel

Filters
List of articles in category Bristol-Myers Squibb
Title Published Date
U.S. Food and Drug Administration approves Opdivo® (nivolumab) + Yervoy® (ipilimumab) for patients with hepatocellular carcinoma (HCC) previously treated with sorafenib 11 March 2020
Voluntis and Bristol-Myers Squibb to co-develop digital therapeutics for oncology 04 March 2020
BioMotiv and Bristol-Myers Squibb announce the launch of Anteros Pharmaceuticals 04 February 2020
U.S. Food and Drug Administration accepts for Priority Review Bristol-Myers Squibb's application for Opdivo (nivolumab) plus Yervoy (ipilimumab) in first-line non-small cell lung cancer 17 January 2020
Bristol-Myers Squibb completes divestment of manufacturing facility in Anagni, Italy 07 January 2020
Bristol-Myers Squibb completes acquisition of Celgene, creating a leading biopharma company 21 November 2019
Bristol-Myers Squibb and Pfizer announce randomized, controlled trial to evaluate the effect of atrial fibrillation screening on health outcomes in older individuals 15 November 2019
Bristol-Myers Squibb awards "Golden Tickets" for LabCentral to Carmine Therapeutics, STIMIT 31 October 2019
The Bristol-Myers Squibb-Pfizer Alliance and Fitbit collaborate to address gaps in atrial fibrillation detection with the aim of accelerating diagnosis 18 October 2019
Bayer, Bristol-Myers Squibb and Ono Pharmaceutical enter into a clinical collaboration agreement 18 July 2019
Bristol-Myers Squibb provides update on pending merger with Celgene 24 June 2019
Bristol-Myers Squibb announces post-closing leadership team 05 June 2019
Award-winning actor and producer Sterling K. Brown joins Bristol-Myers Squibb in effort to share stories of What It's Like to Live with Cancer Today 16 May 2019
Bristol-Myers Squibb reports first quarter financial results 25 April 2019
Bristol-Myers Squibb shareholders approve Celgene acquisition 12 April 2019
European Commission approves Opdivo (nivolumab) plus low-dose Yervoy (ipilimumab) for first-line treatment of patients with intermediate- and poor-risk advanced renal cell carcinoma 15 January 2019
Bristol-Myers Squibb to acquire Celgene to create a premier innovative biopharma company 03 January 2019
Bristol-Myers Squibb and Boston Medical Center announce research collaboration to investigate markers of immuno-oncology response and resistance 17 December 2018
Bristol-Myers Squibb awards "Golden Tickets" for LabCentral to ReviveMed, Strand Therapeutics 26 November 2018
Bristol-Myers Squibb and Compugen announce clinical collaboration to evaluate therapeutic regimen in advanced solid tumors 11 October 2018
  • Start
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • Next
  • End
Health data interoperability: Opportunities and threats

Business & Industry

  • Valneva switches focus to bilateral discussions to supply its inactivated, adjuvanted COVID-19 vaccine candidate VLA2001
  • Pfizer and BioNTech to supply the European Union with 100 million additional doses of COMIRNATY®
  • Amgen successfully completes acquisition of Five Prime Therapeutics
  • GSK and Vir Biotechnology announce EMA review of dual-action monoclonal antibody VIR-7831 for the early treatment of COVID-19
  • Phase III prevention trial showed subcutaneous administration of investigational antibody cocktail casirivimab and imdevimab reduced risk of symptomatic COVID-19 infections by 81%

Research & Development

  • Differing immune responses discovered in asymptomatic cases vs those with severe COVID-19
  • Patients who are obese or overweight are at risk for a more severe course of COVID-19
  • New COVID-19 vaccine may offer broad protection from coronaviruses
  • SARS-CoV-2: New findings on the persistence of neutralizing antibodies
  • Massive fragment screen points way to new SARS-CoV-2 inhibitors
  • B.1.1.7. variant more transmissible, does not increase severity, Lancet studies suggest
  • COVID-19 causes 'unexpected' cellular response in the lungs

Conferences & Events

  • Scientists urge for investment now in highly potent vaccines to prevent the next pandemic
  • CPhI Worldwide to return in 2021
  • Reuters Events' Cell & Gene Therapy USA
  • Total health: Build a better healthcare system
  • Don't fall for the 'next best action' trap
  • Locking down shape-shifting spike protein aids development of COVID-19 vaccine
  • COVID-19 vaccine innovation could dramatically speed up worldwide production

Regulatory Affairs

  • FDA revokes emergency use authorization for monoclonal antibody Bamlanivimab
  • Joint CDC and FDA statement on Johnson & Johnson COVID-19 vaccine
  • AstraZeneca's COVID-19 vaccine: EMA finds possible link to very rare cases of unusual blood clots with low blood platelets
  • Increase in vaccine manufacturing capacity and supply for COVID-19 vaccines from AstraZeneca, BioNTech/Pfizer and Moderna
  • EMA's safety committee continues investigation of COVID-19 Vaccine AstraZeneca and thromboembolic events
  1. You are here:  
  2. Home
  3. Bristol-Myers Squibb

About

  • Home
  • Advertise
  • Privacy
  • Terms of Use
  • Contact

Top News Channels

  • Industry
  • Research
  • Regulatory

Submit Your News!

Follow / Join us

Didn't we got you connected? If not, please note the following magic buttons:
  • Facebook
  • Twitter
  • LinkedIn
  • XING
  • RSS

Digest World Pharma Newsletter

Subscribe to our weekly Digest Newsletter and stay updated on the latest World Pharma News. Subscribe now, it's free!

© World Pharma News 2021. All Rights Reserved.